English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Psoriasis is a chronic inflammatory skin disease associated with quality of life (QoL) impairment.  BRIDGE  was a randomized, double‐blind, phase  III  study comparing the efficacy and safety of dimethylfumarate ( DMF ) with a fixed combination of fumaric acid esters ( FAE ) or placebo for the treatment of moderate‐to‐severe psoriasis.    Objectives  This post hoc analysis investigated treatment effect on QoL overall and by patient subgroups categorized by disease severity. Week 8 efficacy responses were also investigated as possible predictors of Week 16 Dermatology Life Quality Index ( DLQI ) outcomes.    Methods  Patients were randomized to receive a maximum daily dose of 720 mg of  DMF ,  FAE  (gradual up‐titration) or placebo for 16 weeks. Psoriasis Area Severity Index, Body Surface Area, Physician's Global Assessment and  DLQI  were assessed at baseline, Weeks 8 and 16.  DLQI  0‐1 indicated ‘no effect on patient life’. Associations between baseline severity, Week 16  DLQI  and Week 8 efficacy (as observed cases) were also examined.    Results  At baseline, 671 patients were included in the full analysis set (267 randomized to  DMF , 273 to  FAE  and 131 to placebo).  DMF  was superior to placebo ( P  < 0.001) and not significantly different to  FAE  regarding Week 16  DLQI  outcomes ( P  > 0.05). Baseline disease severity did not impact  DLQI  outcomes at Week 16. In  DMF ‐ and  FAE ‐treated patients, Week 8  PASI  50/75 responders reported better  DLQI  responses at Week 16 vs non‐responders ( P  < 0.05). Week 8  PASI  ≤ 3 and/or  PGA  0‐1 responders were also more likely to report  DLQI  0‐1 at Week 16 vs non‐responders ( P  < 0.05).    Conclusion  Dimethylfumarate significantly improved  DLQI  outcomes vs. placebo and was not affected by baseline disease severity. Efficacy responses ( PASI  50/75,  PASI  ≤3 and  PGA  0‐1) as early as Week 8 were predictive of QoL outcomes at Week 16 in  DMF ‐ and  FAE ‐treated patients.

journal of the european academy of dermatology and venereology

Quality of life outcomes in adults with moderate‐to‐severe plaque psoriasis treated with dimethylfumarate ( DMF ): a post hoc analysis of the  BRIDGE  study